Xofigo may improve survival time for prostate cancer patients

07/18/2013 | HealthDay News

Clinical trial data indicated the drug Xofigo, which emits radioactive particles, may increase survival and improve quality of life for men whose advanced prostate cancer has spread to the bones, U.K. researchers reported in the New England Journal of Medicine. Patients lived four months, or 30%, longer with the drug, which was approved by the FDA in May, compared with a placebo.

View Full Article in:

HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC